What is it about?
The Alzheimer's disease – an age-related neurodegenerative disorder leading to a progressive cognitive impairment – is characterized by an intracerebral accumulation of soluble β-amyloid (Aβ) oligomers, followed by the appearance of abnormally ubiquitinylated neurofibrillary tangles – a process associated with a chronic inflammation. The systematic presence of ubiquitinylated inclusions reflects a decrease in the proteasome activity due to (and contributing to) the presence of Aβ oligomers – a central dysfunction in the etiology of the disease.
Featured Image
Why is it important?
The involvement of the ubiquitin-proteasome system opens new therapeutic perspectives for both prevention and treatment. In particular, the potential for synergistic strategies combining diet-derived proteasome activators, immunoproteasome inhibitors and modulators of β-amyloid peptide aggregation to prevent, delay or even reverse the disease progression over time is currently arousing growing interest.
Perspectives
From that perspective, and in light of the recent advances in the understanding of the key molecular and cellular mechanisms underlying the Alzheimer's disease pathogenesis, the present review highlights the mechanisms of action and the preventive and therapeutic potential of some diet-derived bioactive compounds and other natural substances of interest.
Dr Philippe Yves Rémy SIMON
French Army Health Service
Read the Original
This page is a summary of: Alzheimer's disease, β-amyloid peptides and ubiquitin-proteasome system: nutritherapeutic insights, Neurodegenerative Diseases, March 2025, Karger Publishers,
DOI: 10.1159/000545170.
You can read the full text:
Contributors
The following have contributed to this page
